Tryp Therapeutics Inc. TRYPF Archives - Page 3 of 8

ThursdayOct 21, 2021 12:25 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announced Inclusion in AdvisorShares Psychedelics ETF; KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

Tryp announced its inclusion in the AdvisorShares Psychedelics ETF The company hopes that its participation will open it up to a more diverse shareholder base and broaden its life science exposure Tryp’s presentation at the KCSA Virtual Investor Conference will also be available for on-demand viewing over the next 90 days Launched back in September 2021, the AdvisorShares Psychedelics Exchange-Traded Fund (“ETF”) has been actively trading, focusing on enterprises that have devoted a significant proportion of their assets to psychedelic drug development. Operating under the ticker symbol “PSIL” on the New York Stock Exchange (“NYSE”) Arca exchange, this fund has…

ThursdayOct 21, 2021 9:50 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Clinical Hold on Planned Eating Disorder Phase 2a Study

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, reported that the U.S. Food and Drug Administration ("FDA") has placed a clinical hold on its upcoming Phase 2a study for eating disorders. According to the announcement, the FDA did not cite a reason for the hold but would provide additional information regarding the hold in the next month. Although the study is now on hold, the company noted that it still expects to move forward with plans to file an IND for its Phase 2a study in fibromyalgia; that…

FridayOct 15, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with University of Wisconsin Researchers for Clinical Pharmacology Studies Evaluating TRP-8803

Tryp Therapeutics has partnered with Dr. Paul Hutson and Dr. Christopher Nicholas, researchers at the University of Wisconsin-Madison The collaboration will focus on a clinical pharmacology studies to evaluate the safety and pharmacokinetics of TRP-8803, Tryp’s proprietary drug formulation The partnership is the latest in a series of collaborations as the company prepares for Phase 2b trials Tryp intends to use data from its Phase 2a clinical studies, expected to launch this year, coupled with preclinical data and clinical pharmacology data for TRP-8803, to support the use of the novel drug formulation in Phase 2b trials Tryp Therapeutics (CSE: TRYP)…

ThursdayOct 14, 2021 12:47 pm

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Included in AdvisorShares Psychedelics ETF

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has announced its inclusion in the AdvisorShares Psychedelics ETF (the “Fund”), currently trading under ticker symbol PSIL on the NYSE Arca exchange. According to the update, the Fund, launched in September 2021, is actively trading and focuses on companies that devote a majority of assets to psychedelic drug development. The Fund has built a portfolio including over 25 psychedelic companies. PSIL represents an exciting milestone for Tryp with the potential to bring a more diverse shareholder base and to broaden life science exposure for…

TuesdayOct 12, 2021 11:27 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at KSCA Psychedelics Virtual Investor Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the KCSA Psychedelics Virtual Investor Conference at 3:00 p.m. ET on Oct. 14, 2021. The event is slated to take place virtually on Oct. 13-14, 2021. Tryp’s Chief Financial Officer Luke Hayes will provide a live overview of the company's activities and elaborate on how Tryp is leading the next wave of psychedelic drug development beyond mental health with its focus on chronic pain and other indications. Interested parties should visit https://ibn.fm/1Y2RX to…

MondayOct 11, 2021 1:26 pm

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Preparing for Clinical Trials Amid Growing Push for New Federally Approved Therapeutic

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) expects to soon launch a phase 2a clinical trial to determine the efficacy of its psychedelic drug candidate TRP-8802 in treating Prader-Willi Syndrome, hypothalamic obesity eating disorder resulting from removal of a brain tumor, and binge eating disorder. According to a recent article, TRP-8802 will be used in combination with psychotherapy under professional care to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect. Tryp then plans to proceed into phase 2b clinical trials with drug candidate TRP-8803 to test the trademarked product’s ability to penetrate the natural blood-brain…

FridayOct 08, 2021 1:47 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Launch of New Website and Resources

Tryp Therapeutics recently launched a new website with updated resources to be featured on the site Over the next few weeks, the company will share key resources that will be the standout features of the new website Tryp believes that the new features represent expanded knowledge of the company’s strategy and will present more opportunities to existing investors and bring in more individuals who share in its course Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has, since its inception, led the next wave of psychedelic drug development beyond mental health. Its focus on areas of high unmet medical needs and bring…

ThursdaySep 30, 2021 10:56 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Achieves Most Important Milestone Yet with Submission of IND Application for Phase 2a Clinical Trial

Tryp Therapeutics on September 22 submitted an IND application to the FDA to evaluate its oral formulation of synthetic psilocybin, TRP-8802, in a Phase 2a clinical study The study seeks to evaluate TRP-8802 for the treatment of patients with eating disorders and will enroll 10 patients According to Tryp Chairman and CEO, the submission is the first of several IND filings the company intends to make in the coming months Tryp is also preparing for Phase 2b clinical trials, which will evaluate its proprietary drug candidate, TRP-8803 During a recent investor presentation, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical…

MondaySep 27, 2021 11:56 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Working to Bring Psychedelic Treatments Closer to the People

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is contributing to the ongoing conversation around the use of psychedelics in the field of medicine, thereby stamping its position as a leader in the psychedelic renaissance. This follows efforts by the scientific community in the 21st century to prove the potential of psychedelics to rewire or repair circuits in the brain. Specifically, Tryp is bringing light to psilocybin usage in diseases with high unmet needs, including chronic pain, through its Psilocybin-For Neuropsychiatric Disorders (TM) (“PFN”) program. “With its three strategic initiatives — develop, protect and monetize — Tryp remains committed to utilizing FDA’s…

ThursdaySep 23, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Continues to Increase Awareness of Novel Psychedelic Drug Candidates

Pharmaceutical company Tryp Therapeutics is preparing for clinical trials evaluating synthetic formulations of psilocybin to treat medical conditions with underpinning neurological causes The clinical trials planned are being conducted in partnership with research teams at the University of Florida and the University of Michigan Tryp executives have been meeting with investors at select conferences recently to increase awareness, including the just-completed Sept. 21 presentation at Oppenheimer’s Fall Healthcare Life Sciences & MedTech Summit The company expects to initiate Phase 2a trials to begin before the end of the year for treating certain eating disorders, with Phase 2b trials to follow…

Site Search

Company Search

Tag: Tryp Therapeutics Inc. TRYPF